General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Novartis Direct Share Purchase Plan

Novartis offers you the opportunity to participate in the Novartis Direct Share Purchase Plan. The Direct Share Purchase Plan enables you to acquire Novartis Registered Shares and to hold them free of charge in a Share Deposit Account. You may increase your holding by an uncomplicated and inexpensive procedure, by investing up to CHF 200,000 per calendar year in additional Novartis Shares and/or using dividends from Novartis AG for the acquisition of further Novartis Shares. The application to enter your Novartis Shares in the Novartis Share Register will be processed automatically through the Direct Share Purchase Plan.

The Direct Share Purchase Plan is operated by Novartis in cooperation with SIX SAG Ltd. You will maintain contact mainly with SIX, which administers the Direct Share Purchase Plan on behalf of Novartis.

The Direct Share Purchase Plan is open to shareholders and investors residing in Switzerland.

Stock chart
Q1 Results 2015

On Thursday, April 23, Novartis will announce its results for the first quarter of 2015